



**FRESENIUS
KABI**



Sugammadex 200 mg/2 mL Fresenius

Solution for injection


200 mg/2 mL

A:34, OTHER/ANDER

S4 SUGAMMADEX 200 mg/2 mL FRESENIUS
Solution for injection/Oplossing vir Inspuiting

Sugammadex
Single IV use only/Slegs vir enkel IV gebruik
Per 2 mL contains sugammadex sodium equivalent to 200 mg sugammadex. Sugar Free.
Elke 2 mL bevat natriumsugammadeks gelykstaande aan 200 mg sugammadeks. Suikervry.
Posology and directions for use: See enclosed professional information.
Posologie en gebruiksaanwysings: Sien ingeslote professionele inligting.
10 x 2 mL vials/flessies

**FRESENIUS
KABI**



NAPPI code

3009166001 | Pack quantity: 10

Therapeutic indications

SUGAMMADEX FRESENIUS is indicated for the routine reversal of neuromuscular blockade induced by rocuronium or vecuronium.

SUGAMMADEX FRESENIUS is also indicated for the immediate reversal of neuromuscular blockade at 3 minutes after administration of rocuronium.

For the paediatric population, SUGAMMADEX FRESENIUS is only recommended for routine reversal of rocuronium-induced blockade in children above 7 years of age.

Dosage

ADULTS:

The recommended dose of Sugammadex depends on the level of neuromuscular blockade induced by rocuronium or vecuronium and not on the anaesthetic regimen:

Routine reversal: Moderate block	Routine reversal: Deep block	Immediate reversal
Rocuronium & Vecuronium	Rocuronium & Vecuronium	Rocuronium
Spontaneous recovery has occurred up to at least the reappearance of second twitch (T_2)	Recovery has reached at least 1 - 2 post-tetanic counts (PTC)	Reversal at 3 minutes following administration of rocuronium
Sugammadex 2 mg/kg	Sugammadex 4 mg/kg	Sugammadex 16 mg/kg

CHILDREN AND ADOLESCENTS:

For children and adolescents (7 - 17 years) the recommended dose of Sugammadex depends on the level of neuromuscular blockade induced by rocuronium and not on the anaesthetic regimen:

Routine reversal: Moderate block	Routine reversal: Deep block	Immediate reversal
Rocuronium	Rocuronium	Rocuronium
Spontaneous recovery has occurred up to at least the reappearance of second twitch (T_2)	Spontaneous recovery has occurred up to at least the reappearance of second twitch (T_2)	Immediate reversal in children and adolescents has not been investigated
Sugammadex 2 mg/kg	Sugammadex 2 mg/kg	


Sugammadex Fresenius Kabi 100 mg/mL may be diluted to 10 mg/mL to increase the accuracy of dosing in the paediatric population.

The use of SUGAMMADEX FRESENIUS in children < 7 years of age and neonates is not recommended.

Reversal from different depths of NMB is significantly faster with Sugammadex than with Neostigmine¹

Sugammadex rapidly reverses NMB¹

SUGAMMADEX FRESENIUS can be used to reverse different levels of rocuronium or vecuronium induced neuromuscular blockade.



International Guidelines recommend Sugammadex for reversal of NMB²


Both the European Society of Anaesthesiology and Intensive Care (ESAIC) and the American Society of Anesthesiologists (ASA) recommend **Sugammadex for reversal of deep, moderate and shallow block** induced by Rocuronium or Vecuronium.³

Shelf life and Storage

- 3 years shelf life
- Store at or below 30 °C
- After opening and dilution, store at 2 - 8 °C and use within 24 hours

Peel-off label to facilitate correct syringe preparation

- Clear legibility of drug name and total dose per vial
- Simplified workflow



References:

1. Hristovska AM *et al.* Cochrane Database of Systematic Reviews 2017; Issue 8: Art. No.: CD012763.
2. Thilen R *et al.* Anaesth 2023;138:13-41.
3. Fuchs-Buder T *et al.* Eur J Anaesthesiol 2023;40(2):82-94.

[S4] Sugammadex 200 mg/2 ml Fresenius: Each 2 ml vial contains sugammadex sodium equivalent to sugammadex. Reg.No.: 56/34/0944

For full prescribing information refer to the latest professional information approved by the South African Health Products Regulatory Authority.

IMB_118_2_2025_V1